Promethera has outstanding capabilities and expertise in liver biology and cell-based medicine. The Company is open to discuss several opportunities with future partners with aligned areas of interest.
Promethera is dedicated to pioneering the space of cell-based medicines with its unique set-up of liver-derived allogenic cell therapies. While the Company is currently focused on pursuing its internal development plan with HepaStem in the indications ACLF and NASH, Promethera is always interested in new collaborations with industry partners and academic institutions with complimentary interests.
Promethera is looking to bring its strong scientific, preclinical and early-stage clinical development expertise into strategic collaborations, in which the Company would continue to act as the center of excellence for the jointly developed cell therapy products.
Please contact our Business Development team at BD@promethera.com for more information.